Actinium Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Actinium Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the Actinium Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Actinium Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Actinium Pharmaceuticals, Inc.

The report provides overview of Actinium Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Actinium Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Actinium Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Actinium Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Actinium Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Actinium Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Actinium Pharmaceuticals, Inc. Snapshot 5

Actinium Pharmaceuticals, Inc. Overview 5

Key Information 5

Key Facts 5

Actinium Pharmaceuticals, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Actinium Pharmaceuticals, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Actinium Pharmaceuticals, Inc. - Pipeline Products Glance 12

Actinium Pharmaceuticals, Inc. - Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Actinium Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Actinium Pharmaceuticals, Inc. - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Actinium Pharmaceuticals, Inc. - Drug Profiles 16

Iomab-B 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Actimab-A 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

BC-8Y90 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

BC-8SA 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Actimab-B 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Actimab-Br 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Actimab-C 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Actimab-P 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibody Conjugate for Hematological Tumor and Oncology 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibody Conjugate for Oncology 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Actinium Pharmaceuticals, Inc. - Pipeline Analysis 28

Actinium Pharmaceuticals, Inc. - Pipeline Products by Target 28

Actinium Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 29

Actinium Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 30

Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 31

Actinium Pharmaceuticals, Inc. - Recent Pipeline Updates 32

Actinium Pharmaceuticals, Inc. - Dormant Projects 41

Actinium Pharmaceuticals, Inc. - Discontinued Pipeline Products 42

Discontinued Pipeline Product Profiles 42

Bismab-A 42

Actinium Pharmaceuticals, Inc. - Locations And Subsidiaries 43

Head Office 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Actinium Pharmaceuticals, Inc., Key Information 5

Actinium Pharmaceuticals, Inc., Key Facts 5

Actinium Pharmaceuticals, Inc. – Pipeline by Indication, 2016 8

Actinium Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Actinium Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Actinium Pharmaceuticals, Inc. – Phase III, 2016 12

Actinium Pharmaceuticals, Inc. – Phase II, 2016 13

Actinium Pharmaceuticals, Inc. – Phase I, 2016 14

Actinium Pharmaceuticals, Inc. – Preclinical, 2016 15

Actinium Pharmaceuticals, Inc. – Pipeline by Target, 2016 28

Actinium Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 29

Actinium Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 30

Actinium Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 31

Actinium Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 32

Actinium Pharmaceuticals, Inc. – Dormant Developmental Projects,2016 41

Actinium Pharmaceuticals, Inc. – Discontinued Pipeline Products, 2016 42

List of Figures

List of Figures

Actinium Pharmaceuticals, Inc. – Pipeline by Top 10 Indication, 2016 7

Actinium Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Actinium Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Actinium Pharmaceuticals, Inc. – Pipeline by Target, 2016 28

Actinium Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 29

Actinium Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 30

Actinium Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 31

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports